Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Classifica tra le azioni #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Prezzo delle azioni
$62.26
Ultima sincronizzazione: 2026-09-22
Capitalizzazione di mercato
$127.18B
Variazione (1 giorno)
-0.78%
Variazione (1 anno)
38.63%
Paese
US
Scambia Bristol-Myers Squibb Company (BMY)

Categoria

Ricavi di Bristol-Myers Squibb Company (BMY)
Ricavi nel Jun 2026 TTM: $49.19B
Secondo gli ultimi rapporti finanziari di Bristol-Myers Squibb Company, i ricavi attuali dell'azienda (TTM) sono pari a $49.19B. Nel 2024, l'azienda ha registrato ricavi di $48.30B un aumento rispetto a i ricavi dell'anno 2023, che erano pari a $45.01B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Bristol-Myers Squibb Company da 2000 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $49.19B 2.06%
2025 $48.19B -0.22%
2024 $48.30B 7.32%
2023 $45.01B -2.50%
2022 $46.16B -0.49%
2021 $46.39B 9.09%
2020 $42.52B 62.62%
2019 $26.15B 15.89%
2018 $22.56B 8.59%
2017 $20.78B 6.94%
2016 $19.43B 17.31%
2015 $16.56B 4.29%
2014 $15.88B -3.09%
2013 $16.39B -7.01%
2012 $17.62B -17.05%
2011 $21.24B 9.03%
2010 $19.48B 3.59%
2009 $18.81B -8.69%
2008 $20.60B 6.46%
2007 $19.35B 8.00%
2006 $17.91B -6.73%
2005 $19.21B -0.89%
2004 $19.38B -7.25%
2003 $20.89B 15.32%
2002 $18.12B -6.71%
2001 $19.42B 6.63%
2000 $18.22B 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
$79.67B 61.97%
US
$97.93B 99.10%
US
$64.39B 30.90%
US
$77.52B 57.60%
CH
$66.40B 35.00%
US